TimesSquare Capital Management LLC Makes New Investment in Krystal Biotech, Inc. $KRYS

Key Points

• TimesSquare Capital Management initiated a position of 111,545 Krystal Biotech shares worth approximately $41.5 million, joining other institutional investors that collectively own 86.29% of the company.
• Krystal Biotech reported quarterly EPS of $1.79, beating estimates of $1.70, while revenue of $119.22 million fell slightly short of the $120.93 million consensus estimate.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and average price target of $365.40; shares recently opened at $335.73.

TimesSquare Capital Management LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 111,545 shares of the company's stock, valued at approximately $41,458,000. TimesSquare Capital Management LLC owned 0.38% of Krystal Biotech as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in KRYS. UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after acquiring an additional 37 shares during the period. Optimize Financial Inc lifted its position in Krystal Biotech by 1.4% in the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock valued at $704,000 after purchasing an additional 40 shares during the period. Regal Investment Advisors LLC boosted its holdings in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock valued at $1,075,000 after purchasing an additional 44 shares in the last quarter. Torray Investment Partners LLC boosted its holdings in Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock valued at $3,108,000 after purchasing an additional 47 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in Krystal Biotech by 0.9% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company's stock worth $1,537,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the company's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares of the company's stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,642 shares of company stock valued at $16,471,923 in the last ninety days. Corporate insiders own 13.10% of the company's stock.

Krystal Biotech Trading Up 1.0%

Shares of KRYS opened at $335.73 on Tuesday. Krystal Biotech, Inc. has a twelve month low of $136.73 and a twelve month high of $382.54. The firm has a market capitalization of $9.94 billion, a P/E ratio of 42.07 and a beta of 0.53. The firm's 50-day moving average is $345.06 and its two-hundred day moving average is $299.80.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on KRYS shares. Evercore reissued an "outperform" rating and set a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. Citigroup lifted their price target on Krystal Biotech from $378.00 to $386.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. TD Cowen upped their price objective on Krystal Biotech from $306.00 to $403.00 and gave the stock a "buy" rating in a report on Thursday, June 18th. Jefferies Financial Group reiterated a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Finally, Wall Street Zen downgraded Krystal Biotech from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source